A new report from a group of transgender ideology activists has published survey data that conflicts sharply with a recently published study review from the American College of Pediatricians (ACPeds) on the efficacy of sex-change surgeries and pharmaceutical interventions.
The National Center for Transgender Equality (NCTE), an activist group formed in 2003, released the preliminary analysis of the findings for its 2022 U.S. Trans Survey (USTS), which, for the most part, appear very positive for trans activists.
“The U.S. Trans Survey is the largest survey of trans people, by trans people, in the United States,” said the survey’s website.
The NCTE explicitly advocates for changes in public policy in order to further the goals of transgender activists. Conveniently, the preliminary results of the survey supported transgender activists’ narratives and policy preferences in almost all cases.
The NCTE’s survey was not conducted using random samples of trans people, instead using various outreach methods, including entering respondents for a chance to win cash prizes, to receive as many responses as possible.
The survey found that the vast majority of respondents claimed to be happier after transitioning, receiving cross-sex hormones, or transgender surgeries.
“Nearly all respondents (97%) who had at least one form of surgery for their gender identity/ transition reported that they were either ‘a lot more satisfied’ (88%) or ‘a little more satisfied’ (9%) with their life,” said the survey.
On the same day that the USTS preliminary results were released, the American College of Pediatricians (ACPeds) released far different findings on transgender procedures and drugs.
Following a review of 60 scientific studies into the health outcomes following sex-change medical interventions, the ACPeds determined that transgender adolescents had drastically higher rates of mental illness and suicidal ideation than non-transgender minors.
The ACPeds study also seemingly contradicted the USTS results that suggested transgender individuals were far happier after receiving some sort of surgical or medicinal treatment.
“Social transition, puberty blockers, and cross-sex hormones have no demonstrable, long-term benefit on psychosocial well-being of adolescents with gender dysphoria,” said the ACPeds.
The ACPeds review of studies on the outcomes of sex-change surgeries and drug-based interventions is not the first to call into question the quality of research used to advocate for so-called “gender affirming” care.
In Europe, multiple health agencies have revised guidance for sex-change surgeries and drugs, especially for minors, after determining that the scientific evidence supporting those treatments is lacking.